Progyny, Inc. (PGNY) fair value analysis

Nasdaq · Updated 2026-09-07

Progyny, Inc. is a healthcare company that provides fertility and family-building benefits solutions, offering services such as fertility treatments, adoption assistance, and surrogacy support to employers and their employees. The company operates in the United States, serving as a benefits administrator and care coordinator for its clients.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, PGNY is trading at more than a 25% discount to estimated fair value.

PGNY currently ranks #32 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $31.53
Sector: Healthcare
12-month range: $16.86–$31.53

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Expanding
Revenue growth: Strong
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for PGNY

Our model validated 16 trailing price-to-earnings windows for PGNY, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $16.86–$31.53.
The 14-day relative strength index sits at a neutral 31.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for PGNY
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent PGNY news

TickrTrends' derived news-sentiment signal for PGNY is currently leaning positive, computed from recent coverage.

Progyny: Slow But Consistent Growth With A Pristine Balance Sheet (NASDAQ:PGNY) (seekingalpha.com, 2026-09-05)
TickrTrends take: Progyny operates in the Healthcare sector and carries an undervalued designation from TickrTrends according to current valuation metrics. The company's combination of steady growth momentum and strong balance sheet positioning aligns with characteristics that support the undervalued assessment, as financial strength can provide flexibility for reinvestment or shareholder returns during periods of measured expansion. Investors tracking valuation should monitor whether the company's consistent growth trajectory narrows the gap between current pricing and intrinsic value estimates.
Progyny Sees Utilization Rebound as Early Renewals De-Risk Outlook (finance.yahoo.com, 2026-08-16)
TickrTrends take: Progyny's utilization rebound and early customer renewals suggest improving operational momentum that could support stronger cash generation going forward. Given the Healthcare sector's typical valuation multiples and TickrTrends' current Undervalued assessment, investors focused on valuation metrics should monitor whether this utilization improvement translates into margin expansion and guides the company toward sustainable growth rates. The de-risking effect of early renewals may provide visibility into revenue stability, which is a key factor in justifying any multiple expansion from current levels.

What people are saying

Follow the PGNY conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for PGNY showed a shift this week as the Relative Strength Index moved from oversold territory into neutral zone, suggesting reduced downward momentum in the Healthcare sector stock. The current valuation verdict remains Undervalued, indicating the stock may be trading below its assessed fundamental value.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is PGNY stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), PGNY is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is PGNY's TickrTrends verdict?

PGNY's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does PGNY compare to other Healthcare stocks?

PGNY ranks #32 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is PGNY overbought or oversold?

PGNY's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

PGNY vs AVAH · PGNY vs CI · PGNY vs GEHC · PGNY vs IDXX · PGNY vs INCY